Xylem Inc. (NYSE: XYL) — The Best Water Franchise, De-Rated to Merely Fair, Paying Up for Its Own Self-Help

Independent Equity Research Report date: June 27, 2026 · Price: $116.45 (June 26, 2026 close) · Market cap ~$27.7B · EV ~$30.6B

⚡ Claude’s Take

This block is the author’s own independent opinion and general information only — not investment advice and not a recommendation to buy or sell any security. It is the single place in this article where a directional view and valuation range are expressed; the detailed analysis that follows takes no position and sets no price target.

Verdict: HOLD — accumulate on weakness toward the low-$100s. Not a short. Medium conviction. Fair-value zone ~$118–138; start buying sub-$110, don’t chase above ~$140.

Xylem is the highest-quality way to own the water-infrastructure replacement cycle in the public market — the largest pure-play, a fortress balance sheet (net debt ~0.25–0.6x EBITDA), genuinely sticky franchises (Flygt, Sensus, Wedeco, Bell & Gossett), and a real, measurable margin-self-help program that has lifted EBITDA margin from ~15% to ~21% in three years with a credible path to ~24%. The problem is not the business; it’s the price you pay for it. After running to an all-time high of ~$151 in October 2025, the stock has de-rated ~23% to ~$116, which sounds like an opportunity — and on its own 10-year history it is genuinely at the cheap end (AZI composite valuation percentile ~28th; price-to-book in the 7th percentile; forward EV/EBITDA ~14x vs a 13–27x range). But cross-sectionally it is not cheap at all — ~16x trailing / ~14x forward EV/EBITDA and ~21x forward adjusted P/E is mid-pack against Pentair, Veralto, IDEX, Dover and Graco, and Xylem earns the lowest ROIC (~8%) in that entire peer set, weighed down by the goodwill from the $6.9B all-stock Evoqua deal. So you are paying a quality-industrial multiple for a 2–4% organic grower whose headline returns are sub-double-digit. That is “fair price for a very good business,” not a steal.

The reason I lean constructive rather than neutral: the de-rating has already done most of the work, the downside is cushioned by a balance sheet that just turned the buyback on for the first time in a decade ($1.5B authorization, $581M spent in Q1 alone), and the forward earnings algorithm — mid-single revenue + 70–110bps/yr of margin + buyback + ~$1B/yr of tuck-in M&A — credibly compounds adjusted EPS at low-double-digit to mid-teens without heroic assumptions. Framing: a quality compounder that has corrected to fair value — buy the dips, don’t pay up for the story. This is not a falling knife (fundamentals are improving, not deteriorating) and not deep value (it’s only cheap against itself). Conviction: medium. The single piece of evidence that flips me bullish: two consecutive quarters of ≥4% organic growth with EBITDA margin tracking to the high end of guidance (proves the 80/20 “walk-away” drag is ending and underlying demand is re-accelerating, not just self-help optics). The single piece that flips me bearish: organic growth stalling toward zero after the walk-away headwind rolls off, with margin guidance cut — that would mean the water cycle isn’t turning and the multiple is still too high for the growth.

Catchy tag: “The best house on the water block — but the discount is only to its own past, not to the neighbors.”

📈 Stock Price Action — Five-Year Event Map

Over the last five years Xylem has been, in factor terms, dead money: a ~$116 stock today versus ~$113 at the end of 2021, with a violent round-trip in between. It bottomed near $69 in June 2022 (the rate-shock industrials sell-off), more than doubled to an all-time high of $151.41 on October 29, 2025 as the Evoqua margin story compounded, and has since given back ~23% to $116.45 (June 26, 2026), sitting just above its 52-week low of $105.92 (May 2026). The five-year annualized return is ~+1.2% — the business roughly tripled EPS while the multiple compressed, leaving the stock flat. (Prices adjusted, AZI five-year series; the move is FACT, the attributed driver is INTERPRETATION.)

Cycle narrative. The 2022 trough (#1–2) was macro, not company-specific — a duration-driven de-rating that XYL shared with the entire quality-industrial complex. The Evoqua close (#3) re-based the share count and revenue but did little for the stock immediately because it diluted owners ~24% and depressed headline returns. The 2024–25 advance to the ATH (#4–5) was the market paying up for the margin-self-help proof points as EBITDA margin marched from ~19% to ~21%. The 2025–26 give-back (#6) is the heart of today’s setup: the stock got expensive (~20x EV/EBITDA at the peak) just as organic growth went flat (China −30%, deliberate 80/20 “walk-away” of low-margin revenue, soft Western Europe), and the multiple normalized hard. The recent bounce (#7) is stabilization plus a sell-side upgrade. The stock today is a high-quality compounder that ran too hot, corrected, and now sits at fair-to-slightly-cheap on its own history — the question the rest of this memo answers is whether “cheap vs itself” is enough when it’s only “fair vs peers.”

1. Executive Summary

Xylem is the world’s largest pure-play water-technology company: ~$9.0B of 2025 revenue spanning water and wastewater pumps and transport (Flygt, Godwin), building and industrial water systems (Bell & Gossett, Goulds), smart water and energy metering and analytics (Sensus, Pure Technologies), water treatment (Wedeco, Sanitaire), and — since the May-2023 Evoqua merger — outsourced water and services. It sells into a structurally attractive, defensively positioned end-market: the multi-decade replacement of aging US and European water infrastructure (graded C-/D+ by ASCE), backed by apolitical regulatory mandates (PFAS treatment rules effective 2029, lead-service-line replacement), utility digitization (AMI metering), and a nascent data-center water tailwind. The demand is real, durable, and largely funded by rate-recovered municipal capex rather than the federal budget cycle.

The investment story is margin self-help, not growth. Organic revenue grows mid-single-digits at best (FY26 guide: +2–4% organic, partly masked by deliberate “80/20” pruning of low-margin business). The value creation comes from a genuine operational transformation: EBITDA margin has risen from 15.4% (2020) to 21.0% (2025), with management guiding to 22.9–23.3% in 2026 and targeting ~24%+ thereafter. Combined with a fortress balance sheet (net debt ~0.25–0.6x EBITDA), a newly-activated $1.5B buyback (the first material repurchase program in a decade), ~$1B/year of disciplined tuck-in M&A, and an 8%-raised dividend, the algorithm credibly compounds adjusted EPS at low-double-digit to mid-teens (FY26 adj-EPS guide $5.35–5.60 vs $3.92 GAAP / ~$4.50 adjusted in 2025).

The catch is valuation and returns. Xylem earns the lowest ROIC (~8%) in its flow-control peer set, depressed by ~$8.3B of goodwill from the full-priced, all-stock Evoqua deal that diluted shareholders ~24%. At ~16x trailing / ~14x forward EV/EBITDA and ~21x forward adjusted P/E, the stock is cheap only against its own 10-year history (AZI composite ~28th percentile; price-to-book 7th percentile) — cross-sectionally it is mid-pack versus Pentair, Veralto, IDEX and Dover, and at a discount only to the higher-margin/higher-ROIC names (Badger Meter, Graco, Roper). The re-rating case rests entirely on execution of the margin program and a water-AMI cycle that doesn’t inflect until ~2030 — not on a wide moat or a valuation discount.

Two quality-of-earnings flags temper the self-help narrative: restructuring/realignment charges are rising, not falling (FY25 ~$103–133M, +66% YoY — increasingly a recurring cost dressed as one-time), and management’s incentive plans contain no return-on-capital metric despite having just deployed $6.9B of capital on a ~70%-goodwill acquisition. Insiders are net sellers; the only open-market purchase in five years is a single director’s ~$141k buy near the lows.

Bottom line: a best-in-class water franchise in a good industry, with a fortress balance sheet and a real margin story — that has already de-rated to fair value. The business merits a quality premium; the current price largely embeds it. Reward is in the compounding, not in a re-rating from a discount.

2. Business Overview

Xylem was spun out of ITT Corporation in 2011 as a focused water-technology company and has spent the subsequent decade transforming from a pumps manufacturer into a diversified water-technology platform spanning hardware, software, analytics, and services. It is headquartered in Washington, D.C., employs roughly 23,000 people, and operates in more than 150 countries. The company reorganized into four reportable segments following the Evoqua merger:

Water Infrastructure (~$2.4B revenue, the legacy heart of the company). Water, wastewater, and stormwater pumps; transport and dewatering systems; and treatment equipment (filtration, disinfection, biological treatment). Key brands: Flygt (submersible wastewater pumps — a global #1/#2 franchise), Godwin (mobile dewatering and rental), Wedeco (UV and ozone disinfection), Sanitaire (biological treatment), Leopold and Neptune Benson (filtration). Customers are predominantly municipal utilities. This is the most secular, most defensive, highest-installed-base part of Xylem.

Applied Water (~$1.8B revenue). Pumps, valves, heat exchangers, and controls for commercial buildings, industrial process, agriculture, and residential. Brands: Bell & Gossett (HVAC/building hydronics — a specified, branded leader), Goulds Water Technology (groundwater), A-C Fire Pump, Lowara, Jabsco. This is the most cyclical segment — commercial construction, industrial capex, and residential demand drive it — but also the segment now capturing the data-center water opportunity (Q1-2026 data-center orders alone exceeded all of FY2025).

Measurement & Control Solutions / MCS (~$2.2B revenue). Smart water and energy meters, networked communications, data analytics, and critical-infrastructure assessment. Brands: Sensus (a top-3 North American advanced-metering-infrastructure / AMI franchise), Pure Technologies (leak detection, pipe condition assessment), YSI and WTW (water-quality analytics), Smith-Blair. This segment carries the highest software/recurring content and the clearest secular digitization driver — though it is currently mid-divestiture of a lower-margin international metering business (close expected end of Q2-2026).

Water Solutions & Services / WSS (~$1.9B revenue, primarily the former Evoqua). Outsourced water, mobile and emergency water services, industrial water treatment, environmental remediation, and a large recurring-services tail. This is the segment Xylem bought Evoqua to acquire: it converts one-time equipment sales into multi-year, sticky service relationships. The $850M outsourced-water contract booked in April 2026 — the largest in company history, a 20-year deal that is ~75% recurring service — is the showcase for the WSS model.

How it makes money / revenue quality. Roughly half of Xylem’s revenue is tied to municipal and utility end-markets (the most resilient, rate-recovered demand), with the balance split across industrial, commercial, and residential. The revenue mix is improving toward higher-quality streams: recurring services and software (WSS services tail, Sensus SaaS/analytics, parts and consumables) are growing share, and the company carries a ~$4.7B backlog with book-to-bill above 1.0. Pricing is realized annually and has held positive against inflation through the recent cycle. This is a business with genuine demand durability and improving revenue quality — but it remains, at its core, a hardware-led industrial whose growth is mid-single-digit, not a software company.

Verdict: A well-diversified, brand-led, defensively positioned water-technology platform with improving revenue quality and a genuinely sticky installed base in its best franchises. The four-segment structure spreads risk well; the business is understandable and durable. It is a high-quality industrial — not a high-growth one.

3. Industry Dynamics

Market structure and size. The global water and wastewater treatment equipment market is roughly $71–75B (2025), growing ~5% annually toward ~$100–115B by the early 2030s. Xylem’s broader served market — adding pumps/transport, metering/AMI, analytics, and outsourced services — is larger and more fragmented. At ~$9B revenue Xylem is the largest pure-play participant but still holds only single-digit share of a structurally fragmented global market populated by large private players (Grundfos, KSB), diversified industrials (Pentair, Dover, IDEX, Veralto), and thousands of regional OEMs. There is no dominant share-holder; the industry is consolidating slowly via acquisition (Xylem/Evoqua being the largest recent example).

Demand drivers — secular and largely apolitical. The structural case for water-technology demand is among the most durable in the industrial complex:

• Aging infrastructure. ASCE’s 2025 report card grades US drinking water C- and wastewater D+; the estimated investment gap is well over $1T across 20 years. Much of the US/EU water plant is at or beyond useful life. This is a multi-decade replacement runway, not a cyclical surge.
• Regulatory mandates (the apolitical floor). EPA’s PFAS drinking-water maximum contaminant levels (compliance ~2029) legally compel treatment investment — directly favorable to Xylem’s Wedeco UV/ozone and Evoqua’s ion-exchange/adsorption media. The Lead & Copper Rule Improvements mandate replacement of lead service lines (~4M lines). These mandates force spending regardless of who controls Washington.
• Utility digitization / AMI. The advanced-metering-infrastructure refresh cycle is the clearest digitization driver. Management’s framing: water-AMI adoption runs 5–7 years behind electric-AMI, and the next water-meter refresh wave is expected to accelerate “late this decade into 2030.” Near-term, electric/energy metering is in its refresh; water is the next leg.
• Data-center water (newer, smaller). AI-driven compute is creating new industrial water demand for cooling and process water. Xylem’s own research projects AI value-chain water demand rising sharply by 2050. Concretely, Applied Water’s data-center orders in Q1-2026 exceeded the full-year 2025 total — real and accelerating, but still a small slice of a $9B base.

Funding mechanics. The durable demand backstop is rate-recovered municipal capex plus state revolving funds, not federal grants. Utilities raise water rates to fund prudently-invested capital regardless of the federal cycle (the regulated-water-utility rate-base model — e.g., American Water — drives the same replacement spend Xylem supplies). The IIJA/Bipartisan Infrastructure Law contributed ~$50B of incremental water funding, ~70% of which is already contractually obligated to states; its authorization expires September 30, 2026, and reauthorization is uncertain, with the current administration having proposed EPA budget cuts (including ~31.5% to the SRFs). Interpretation: IIJA is a fading marginal tailwind, not a cliff — it accelerated demand but is not the core engine. The mandate-driven and rate-recovered spend is the floor; federal grants are the kicker.

Competitive intensity and cyclicality. Municipal water capex is the most resilient end-market Xylem serves; the industrial/commercial/residential portion (largely Applied Water) is genuinely cyclical. Competition is real and segment-specific — Grundfos/KSB/Pentair/Franklin in pumps, Badger Meter/Itron/Mueller in metering, Veralto in water-quality analytics. Local OEMs compete on price in commoditized lines. Barriers to entry are moderate and franchise-specific (brand specification, regulatory approvals, installed-base service networks) rather than industry-wide.

Verdict: a structurally good, defensively positioned, mid-single-digit-growth industry. The secular drivers — aging infrastructure, PFAS/lead mandates, AMI refresh, data centers — are real, durable, and largely insulated from politics. They justify resilience and a quality framing, not a hyper-growth multiple. This is a good industry that smooths the trough; it does not turn Xylem into a 10%+ grower.

4. Competitive Position

The central question: does Xylem have a durable, wide moat, or is it a good-but-competitive industrial? The honest answer is the latter — a high-quality industrial with several narrow, per-franchise moats, not a single wide one.

Where the moat is real (per-franchise). Xylem’s durable advantages are concentrated in branded, specified, installed-base-heavy product lines where switching costs are genuine:

• Flygt (submersible wastewater pumps): a global #1/#2 with decades of municipal specification, an installed base that drives replacement-part and service lock-in, and engineering reputation. Municipal buyers specify Flygt by name.
• Sensus (AMI metering): a top-3 North American franchise where utilities make multi-year, sticky network commitments; once a utility deploys a Sensus AMI network, switching is costly and rare.
• Bell & Gossett (building hydronics) and Goulds (groundwater): specified, brand-led franchises with contractor and engineer loyalty.
• Wedeco (UV/ozone disinfection): a technology-and-reference-base advantage that benefits directly from PFAS/disinfection mandates.
• WSS / outsourced water (ex-Evoqua): multi-year service contracts (the $850M, 20-year deal is the archetype) create recurring, relationship-locked revenue with high renewal rates.

In Greenwald’s taxonomy, these are primarily customer-captivity (specification, switching costs, installed-base service) and local/segment scale advantages — genuine but bounded. They are not network effects (pressure-tested: the AMI business has mild network characteristics within a single utility’s deployment but none across utilities) and not a cost moat at the corporate level.

Where the moat is absent. The commoditized portions of the portfolio — basic pumps, components, certain metering hardware — are genuinely contested on price by Grundfos, KSB, Pentair, Franklin Electric, Badger Meter, and regional OEMs. There is no pricing power across the whole portfolio; Xylem realizes price annually but must fight for it.

The financial test — and where the moat narrative breaks down. A moat must show up in returns. Xylem’s do not impress at the corporate level: ROIC of ~8% (FY2025) is the lowest in its entire flow-control peer set (vs Badger Meter ~21%, A.O. Smith ~27%, Graco ~18%, Pentair ~14.5%, IDEX ~9%). The headline ROE of ~28% is a thin-equity/goodwill artifact — it is flattered by the fact that most of Xylem’s equity is goodwill, not by superior cash returns on tangible capital. The ~8% ROIC is depressed by the $8.3B of goodwill from the Evoqua deal, which means Xylem paid a price for Evoqua that capitalizes most of the expected return into the purchase price — the moat exists at the franchise level, but the capital allocation (paying full price for it) has driven blended returns down to roughly the cost of capital. Even pre-Evoqua, Xylem ran high-single/low-double-digit ROIC — respectable for an industrial, but not moat-grade.

Verdict: a durable, quality industrial with narrow per-franchise moats — not a wide-moat compounder. The individual franchises (Flygt, Sensus, Wedeco, Bell & Gossett, WSS) are genuinely sticky and defensible; the conglomerate of them is a good scale-and-distribution story but earns only cost-of-capital returns after the Evoqua goodwill. The quality is real and the franchises will not erode quickly — but if you are underwriting a wide moat that supports a premium multiple, the ~8% ROIC says you are overpaying for the moat narrative. This is a good business bought at a full price, not a fortress earning excess returns on capital.

5. Growth History and Forward Opportunities

Historical growth — acquisition-led, not organic-led. Revenue rose from $4.9B (2020) to $9.0B (2025), but the bulk of that ~85% increase came from the Evoqua merger (which added ~$1.8B+ of revenue from May 2023), not organic compounding. Stripping acquisitions, Xylem’s organic growth has run mid-single-digits through the cycle — roughly 4–7% in good years, flat-to-low in soft ones. The 2020→2022 organic path (~$4.9B→$5.5B) was ~6% annualized; the post-Evoqua organic trend has decelerated to low-single-digits as China weakened and the company deliberately pruned low-margin revenue.

Current growth — flat, and partly self-inflicted. FY2026 guidance is +2–4% organic / +2–3% reported. Q1-2026 was flat organic. Three drags explain the softness, two of them deliberate:

• China −30% (Q1-2026): ~1/3 end-market weakness, ~1/3 competitor pricing actions, ~1/3 Xylem deliberately walking away from low-margin business. ~1% full-year revenue headwind, bottoming in H1-2026.
• 80/20 “walk-away”: Xylem is deliberately shedding low-margin SKUs and customers under its simplification program — a ~200bps drag on organic growth in 2026, front-half weighted, peaking this year. This depresses reported growth while improving margin and returns — a quality-over-quantity trade.
• Western Europe softness and project-timing lumpiness in WSS and MCS.

The honest read: underlying demand-driven organic growth is probably ~4–6%, masked to ~2–4% by the deliberate pruning. Management guides to an H2-2026 reacceleration (a “significant volume ramp”), dependent on booked MCS projects converting — a real but not-yet-proven inflection.

Forward opportunities. The growth algorithm to mid-teens EPS (management’s Investor-Day 2024 framework) rests on: (1) mid-single organic revenue once the walk-away rolls off; (2) the water-AMI refresh cycle inflecting toward 2030 (a multi-year MCS tailwind); (3) data-center water demand scaling in Applied Water; (4) the WSS recurring-services flywheel (large outsourced contracts compounding a service tail); (5) ~$1B/year of tuck-in M&A (e.g., the $219M German water-quality-instruments deal in March 2026); and (6) continued margin expansion converting flat-ish revenue into double-digit profit growth. PFAS and lead mandates provide a regulatory demand pull through the late 2020s.

Verdict: low-to-moderate-quality growth in the near term, improving in the out-years. Today’s growth is flat and partly self-inflicted (deliberate pruning) — defensible because it improves mix and returns, but it is not the high-quality organic compounding a premium multiple implies. The forward opportunity set (AMI 2030, data centers, WSS services, regulatory pull) is genuine and could lift sustainable organic growth back to mid-single-digits, but the inflection is a forward call, not a current fact. The growth case is a “wait for it” story, and the wait is real.

6. Financial Quality

Revenue and margins — the self-help is real and measurable. Revenue grew to $9.0B (2025); the standout is margin. EBITDA margin rose from 15.4% (2020) → 15.8% (2023, depressed by Evoqua integration) → 19.1% (2024) → 21.0% (2025), with FY2026 guidance of 22.9–23.3% (+70–110bps) and a stated ~24%+ target thereafter. Operating margin moved from ~10% to ~15% over the same span. Gross margin has been steady at ~37–38%; essentially all the margin gain is below the gross line — productivity, simplification (80/20), Evoqua synergies, and price-cost discipline. This is a genuine, multi-year operational transformation, not a one-quarter optical move, and it is the legitimate core of the bull case.

Quality of earnings — two real flags. The GAAP-to-adjusted gap is wide and persistent (FY2026 adjusted EPS guide $5.35–5.60 vs ~$3.92 GAAP in 2025). Two items deserve skepticism:

• Acquired-intangible amortization ~$170–200M/year — a permanent, non-cash GAAP drag from the Evoqua purchase-price step-up. This is a legitimate add-back (non-cash, doesn’t recur in cash terms), and adjusting for it is defensible. It explains most of the GAAP-vs-adjusted gap.
• Restructuring/realignment charges are rising, not falling: FY2022 ~$15M → FY2023 ~$76M → FY2024 ~$62–91M → FY2025 ~$103–133M (+66% YoY). This is the less legitimate add-back — when “one-time” restructuring charges grow every year and become a permanent line, they are arguably a recurring cost of running the business being dressed as non-recurring to flatter adjusted earnings. This is a yellow flag on the quality of the “self-help” margin story: some of the reported margin expansion is being purchased with perennial restructuring charges that adjusted EPS conveniently excludes.
• FY2023 tax rate of 4.1% (vs ~18–20% normal) was driven by discrete Evoqua-related items (uncertain-tax-position release + valuation-allowance benefit) — it flattered FY2023 GAAP EPS and is non-repeatable. Normalize it out.

Cash generation — strong and high-quality. Operating cash flow was ~$1.24B in 2025; with capex of ~$280–370M, free cash flow runs ~$0.9–1.0B (management targets a “low-double-digit FCF margin,” ~$0.9–1.1B). FCF conversion of net income is consistently above 100% — a genuine quality marker. The business is asset-light enough (capex ~3–4% of revenue) to fund its dividend, buyback, and tuck-in M&A internally.

Balance sheet — fortress. Net debt of only ~$463M (2025) against ~$1.9B EBITDA is ~0.25x; even after the Q1-2026 buyback and the $1B May-2026 debt issuance, net leverage is ~0.6x — far below the 0.5–1.0x range management targets. Cash of ~$1.5B, an investment-grade credit profile, and ample liquidity. Tangible common equity has rebuilt from negative (2022) to ~16% of assets as retained earnings accumulate. This balance sheet is a genuine strategic asset — it underwrites the buyback, the M&A pipeline, and downside protection.

Returns — the weak spot. As covered in the Competitive Position section, ROIC of ~8% is the lowest in the peer set, dragged by Evoqua goodwill; ROE of ~28% is a goodwill/thin-equity artifact. Returns on tangible and incremental capital are better (incremental operating margin was ~54% in 2025), but the blended return on the full capital base — including what was paid for Evoqua — is only around the cost of capital.

Verdict: economics that are improving with scale, but from a returns base that is merely adequate. The margin trajectory, cash conversion, and balance sheet are genuinely high-quality and the direction of travel is unambiguously positive. The blemishes — rising “one-time” restructuring, a wide adjusted-EPS gap, and cost-of-capital ROIC — mean this is a good industrial getting better, not a fortress compounder. The self-help is real; just don’t pay for it twice.

7. Capital Allocation

Capital allocation is where the Xylem story is most mixed — competent and improving on the margin, but anchored by one very large, full-priced, return-dilutive decision.

The Evoqua merger (May 2023) — the defining capital decision. Xylem acquired Evoqua in an all-stock deal: 0.48 Xylem shares per Evoqua share, 58.8M new Xylem shares issued (~$6.1B of stock), total acquisition-date consideration of ~$6.9B (including $160M of replacement equity awards and $619M of Evoqua debt repaid). The deal created $4.8B of goodwill and $1.8B of intangibles — roughly 70% of the consideration was goodwill. Strategic logic is sound (scale in treatment, a recurring-services platform, PFAS exposure), and integration has gone reasonably well (synergies delivered, WSS performing). But the financial verdict is sober: Xylem diluted existing owners ~24% and deployed $6.9B at a price that capitalizes most of the expected return into the purchase, dragging blended ROIC down to ~8%. This was an empire-scaling deal done at a full price — value-neutral-to-modestly-dilutive on returns, defensible only if the margin/synergy execution and the services flywheel compound for years. The jury is still out, leaning favorable on execution but unproven on returns.

Buybacks — newly activated, opportunistic. For roughly a decade Xylem ran no material repurchase program (the prior authorization dated to August 2015 and still had ~$182M unused at end-2025). In February 2026 the board authorized a fresh $1.5B program, and Xylem deployed $581M in Q1-2026 alone — opportunistically, into the post-de-rating weakness. This is a genuine positive: management is using the fortress balance sheet and a depressed multiple to shrink the share count for the first time in years, and the stated framework (buy more when the stock is dislocated, manage leverage to 0.5–1.0x) is sensible. It is, however, brand new — not a long track record of disciplined repurchase.

M&A pipeline — disciplined, bottom-up tuck-ins. Beyond Evoqua, the current strategy is ~$1B/year of segment-led tuck-ins (the $219M German water-quality-instruments deal in March 2026 is the template). Management has explicitly shifted from “top-down, lumpy, big targets” to “bottom-up, segment-owned, smaller deals” — a more disciplined posture that, if maintained, is the right way to compound. Worth watching that the $1B/year cadence stays accretive on returns rather than reprising the Evoqua dilution at smaller scale.

Dividend — modest, growing, well-covered. The dividend was raised ~8% in January 2026 to ~$1.60/share, a ~41% payout — well-covered by FCF, with a multi-year growth record. Not a high yield (~1.4%), but a reliable, growing return of capital.

The incentive red flag — no return-on-capital metric. The most important capital-allocation finding sits in the proxy: management’s annual bonus is scored on adjusted EBITDA margin + organic revenue + adjusted FCF margin, and the long-term incentive on relative TSR + cumulative adjusted EPS. There is no ROIC, return-on-invested-capital, or return-on-capital metric anywhere in either plan. For a company that just deployed $6.9B on a ~70%-goodwill acquisition and earns the lowest ROIC in its peer group, the absence of any return-on-capital accountability in compensation is a genuine governance flag — it incentivizes margin and EPS (which can be bought with acquisitions and buybacks) without holding management accountable for the returns on the capital deployed to get them. CEO Pine’s FY2025 total compensation was ~$11.3M (~89% performance-based by the proxy’s own measure). Ownership is index-dominated (Vanguard 11.5%, BlackRock 10.0%); insider ownership is diffuse.

Verdict: competent and improving, but not yet proven as value-accretive capital allocation. The newly-activated opportunistic buyback, the disciplined tuck-in framework, and the covered, growing dividend are all positives. They are offset by the large, return-dilutive Evoqua deal and — more structurally — by an incentive system that ignores returns on capital. Management is allocating capital reasonably; it is not yet demonstrably allocating it to maximize per-share value on the capital employed. Watch the buyback cadence and tuck-in discipline; they are the proof points that would upgrade this verdict.

8. Changes and Headwinds — Last Two Years

Leadership transition (completed). Patrick Decker, the long-tenured CEO who led the Evoqua acquisition, retired; Matthew Pine became CEO effective January 1, 2024 (he had been COO from January 2023). CFO Bill Grogan is in seat. The 2026 Q1 call also announced two new executive roles (Chief Growth & Commercial Officer; Chief Innovation & Product Officer) to push the growth agenda. The transition has been orderly; Pine owns the 80/20 simplification and margin-expansion program.

The 80/20 simplification program (in progress, the core operating change). The defining recent strategic shift is the operating-model transformation — simplifying the structure, pruning low-margin SKUs/customers (“walk-away”), and driving productivity. It is the engine of the margin story but is also the cause of the soft near-term organic growth (the ~200bps walk-away drag peaking in 2026). A genuine quality-over-quantity trade.

Portfolio reshaping. Xylem signed (Sept-2025) to divest its lower-margin international metering business (part of MCS; close expected end Q2-2026) — accretive to MCS margins (which should exit the year >25% EBITDA margin post-divestiture). On the buy side, the $219M German water-quality-instruments tuck-in (March 2026) and the $850M largest-ever WSS outsourced-water contract (April 2026) are the growth-side proof points.

Capital-return inflection. The $1.5B buyback authorization (Feb-2026), $581M repurchased in Q1, the 8% dividend raise (Jan-2026), and the $1B debt issuance (May-2026, 5.20%/5.45% notes) together mark a shift toward more aggressive capital return — funded by the fortress balance sheet.

Headwinds. (1) China weakness (−30% in Q1-2026), a mix of market, competitive, and self-inflicted pruning — bottoming but a real drag. (2) Western Europe softness. (3) Tariffs / input-cost inflation — managed via price and fuel surcharges (“price-cost positive”), but a margin-watch item that pressures the 80/20 bridge if metals inflation persists. (4) IIJA reauthorization risk (expires Sept-2026) and proposed EPA budget cuts — a fading federal tailwind, not a base-demand cliff. (5) Flat near-term organic growth — the market’s central worry, and the reason the stock de-rated.

Verdict: the changes net positive for the thesis, the headwinds net manageable but real. The leadership transition, simplification program, portfolio reshaping, and capital-return inflection all strengthen the long-term franchise and the margin trajectory. The headwinds (China, Europe, tariffs, flat organic) are cyclical/transitional and largely understood — they explain the de-rating but do not break the thesis. The key open question is whether the promised H2-2026 organic reacceleration materializes; if it doesn’t, the “self-help masks weak demand” bear case gains force.

9. Risk Analysis (Risk Matrix)

Overall risk read: moderate, skewed toward earnings-trajectory and valuation risk rather than solvency or franchise risk. The fortress balance sheet and essential-product demand make a permanent capital loss highly unlikely; the realistic risk is paying ~21x forward adjusted earnings for a 2–4% organic grower and being disappointed by either growth or multiple. This is a “valuation-and-execution” risk profile, not a “business-quality” one.

10. Valuation Discussion (Embedded Expectations)

Where the stock trades. At $116.45, Xylem carries a market cap of ~$27.7B and EV of ~$30.6B. On trailing numbers: ~16x EV/EBITDA, ~3.4x EV/sales, ~29x GAAP P/E. On forward (FY2026) numbers: ~14.1–14.5x EV/EBITDA (on the $2.11–2.17B EBITDA guide) and ~21x adjusted P/E (on the $5.35–5.60 adjusted-EPS guide). FCF yield is ~3.5% on ~$1B FCF.

Own-history context (the “cheap” part). Against its own 10-year history, Xylem is genuinely at the inexpensive end: the AZI composite valuation percentile is ~28th, with price-to-book in the 7th percentile (cheapest decile of its own range), P/E in the 22nd, and P/S in the 56th. Its own EV/EBITDA range over five years has been ~13–27x; at ~14x forward it sits near the bottom. The stock has compressed from ~20–27x at its 2021/2025 peaks to ~14x today even as EPS roughly doubled — a textbook de-rating of a quality compounder.

Cross-sectional context (the “not cheap” part). Against its peer set, Xylem is mid-pack, not cheap: ~16x trailing EV/EBITDA sits below Badger Meter (~21x), Graco (~19x), Dover (~17x), Veralto (~17x), and IDEX (~16x); roughly in line with Pentair (~16x) and Roper (~15x); and above the lower-quality water names (Mueller ~13x, A.O. Smith ~12x, Franklin ~13x). Critically, Xylem earns the lowest ROIC (~8%) in this group while trading at a mid-pack multiple — so the market is already paying a quality-and-self-help premium relative to current returns. The “discount” is to its own past, not to its competitors.

Embedded expectations. At ~14x forward EV/EBITDA and ~21x forward adjusted P/E for a business guiding to +2–4% organic growth and ~23% EBITDA margins, the market is pricing continued margin expansion toward ~24%+ and a return to mid-single-digit organic growth as the 80/20 walk-away rolls off — i.e., it is underwriting the management algorithm (mid-single revenue + steady margin gains + buyback + tuck-ins → low-double-digit to mid-teens adjusted-EPS growth). What the market is arguably pricing correctly: the margin trajectory and balance-sheet quality. What it may be pricing too optimistically: the organic-growth reacceleration (still unproven) and a multiple that assumes the self-help continues indefinitely despite a ~8% ROIC. What it may be under-appreciating: the optionality in the water-AMI 2030 refresh and the WSS services flywheel, plus the newly-activated buyback shrinking the share count into weakness.

Scenario analysis (illustrative, not a price target):

• Bear (~$95–110): organic growth stalls toward zero after walk-away rolls off, margin guide trimmed, multiple compresses to ~12–13x forward EBITDA / ~18x adjusted EPS. ~$5.00–5.20 adjusted EPS × ~19x ≈ $95–100; or ~13x × ~$2.0B EBITDA ≈ $103.
• Base (~$118–138): the algorithm works — mid-single organic returns, EBITDA margin to ~23–24%, adjusted EPS ~$5.50–6.10, multiple holds ~15–16x forward EBITDA / ~21–23x adjusted EPS. ≈ $127–139 on EBITDA; ≈ $116–126 on P/E. Center of gravity ~$125–130.
• Bull (~$150–170): organic reaccelerates to mid-single+, AMI/data-center optionality is credited, margin reaches ~24%+, buyback compounds, multiple re-rates back toward ~17x forward EBITDA / ~25x adjusted EPS. ~$6.00+ adjusted EPS × ~25x ≈ $150; ~17x × ~$2.2B EBITDA ≈ $148–155+.

No price target and no recommendation (the directional view lives only in the author’s opinion block above). The valuation conclusion: the stock has de-rated to roughly fair value on its own history and slightly-rich-to-fair on a cross-sectional, returns-adjusted basis. The reward is in the forward compounding, not in closing a discount.

11. Variant Perception

Consensus view. The sell-side and market consensus is broadly constructive-but-patient: Xylem is a high-quality water-technology compounder executing a credible margin-expansion program, with a fortress balance sheet and durable secular demand, that got ahead of itself into late 2025 and has corrected to a more reasonable level. The recent Jefferies upgrade to Buy (PT $140, June 2026) and street targets in the ~$140–157 range reflect a view that the de-rating is an entry point and the margin story has further to run. Consensus expects the H2-2026 organic reacceleration to materialize.

Strongest bull case. Xylem is the single best public vehicle for the multi-decade water-replacement supercycle, with apolitical regulatory mandates (PFAS, lead) forcing demand and an AMI refresh cycle that inflects toward 2030. The 80/20 transformation is a genuine, durable margin engine (15%→21%→24%+), the balance sheet is pristine, the buyback is newly activated into weakness, and the EPS algorithm compounds at low-double-digit to mid-teens. At ~14x forward EBITDA — the low end of its own history — you are buying a quality compounder at a rare discount to itself, with optionality (AMI 2030, data centers, WSS flywheel) you’re not paying for.

Strongest bear case. Xylem is a 2–4% organic grower earning ~8% ROIC — the lowest in its peer group — trading at ~21x forward adjusted earnings that exclude a rising tide of “one-time” restructuring charges. The margin story is partly purchased with perennial restructuring, the Evoqua deal diluted owners ~24% at a full price and there is no ROIC metric in compensation to prevent a repeat, insiders are net sellers, and the “cheap vs own history” framing ignores that the stock is mid-pack-to-rich versus peers on a returns-adjusted basis. If the promised organic reacceleration doesn’t come, the multiple has further to fall toward the low-ROIC names (~12–13x), implying ~$95–105.

The 3–5 assumptions that matter most:

1. Does organic growth reaccelerate to mid-single-digits in H2-2026 and beyond, once the 80/20 walk-away rolls off? (The single most important swing factor.)
2. Does EBITDA margin reach and hold ~24%+ — and is it “real” margin or restructuring-purchased?
3. Does the water-AMI refresh cycle actually inflect ~2030, giving MCS a multi-year tailwind?
4. Does management allocate the ~$1B/year M&A and the buyback accretively — or repeat the Evoqua full-price dilution?
5. Does the multiple hold ~14–16x forward EBITDA, or compress toward the low-ROIC peers if growth disappoints?

Factor-positioning read (the tape as evidence). The quantitative picture corroborates the “de-rated, out-of-favor quality” framing rather than a falling-knife or a crowded-momentum setup. Xylem carries a beta of ~0.91, negative recent alpha, and poor relative strength (rs_6m −15%, rs_peak −23%, 1-year return −9% with negative Sharpe across short horizons) — it has been a market-lagging, low-momentum name. Its factor loadings are style-neutral-defensive: positive Dividend Yield (+0.23/+0.27) and a modest Small-Size tilt, negative Growth (−0.11) and Oil-Price (−0.16), with no Momentum, Value, or Quality loading — i.e., the market is treating it as a defensive, slightly-out-of-favor industrial, not as a momentum darling or a deep-value name. The five-year annualized return is ~+1.2% (dead money). Interpretation (regime-caveated, not a price call): this is consistent with a quality compounder that has been abandoned by momentum and not yet rediscovered by value — the setup where patient accumulation is rewarded if the fundamental algorithm delivers, and where the downside is cushioned by the defensive factor profile and fortress balance sheet. It is not the profile of a deteriorating business (no high-beta falling-knife signature) nor of a crowded trade at risk of unwinding.

Where consensus may be offsides: consensus is probably right that the business is high-quality and the de-rating overdone on a 3-year view, but may be too sanguine on the timing and certainty of the H2-2026 organic reacceleration, and too forgiving of the gap between an ~8% ROIC and a quality-premium multiple. The variant perception is less “consensus is wrong about the company” and more “consensus is paying for an algorithm that requires proof, at a price that already embeds the quality.”

12. Fact vs. Interpretation Table

13. Open Questions

1. Will H2-2026 organic growth reaccelerate to mid-single-digits as guided — or is flat-to-low organic the new normal once the 80/20 walk-away rolls off? (The thesis hinges here.)
2. How much of the EBITDA-margin expansion is durable vs purchased with rising restructuring charges? What does the “clean” margin look like once realignment normalizes?
3. When does the water-AMI refresh cycle actually inflect — is 2030 a firm date or a perennially-receding horizon?
4. Will the $1B/year M&A cadence stay return-accretive, or reprise the Evoqua full-price dilution at smaller scale? And will the board ever add a return-on-capital metric to compensation?
5. What is the post-divestiture run-rate? Once the international metering business is sold (end Q2-2026), what is the clean revenue/margin base for MCS and the company?
6. How large can the WSS outsourced-water flywheel become? Is the $850M, 20-year contract a one-off or the first of a repeatable pipeline?
7. What is Xylem’s normalized ROIC trajectory — does it climb meaningfully above the cost of capital as Evoqua synergies mature, or is ~8–10% the ceiling on a goodwill-laden base?

14. What Must Be True

For the bull case to work:

• Organic growth must return to and sustain mid-single-digits once the 80/20 walk-away rolls off (FY2027+), demonstrating the secular demand drivers are real and the pruning was quality-accretive, not demand-masking.
• EBITDA margin must reach and hold ~24%+ on a clean basis (not perpetually re-supported by rising restructuring), proving the self-help is durable.
• Capital allocation must compound per-share value — buyback shrinking the count into weakness, tuck-ins staying accretive, no repeat of full-price dilution.
• Falsification test: two-plus consecutive quarters of flat-to-negative organic growth after the walk-away headwind has rolled off (H2-2026 / 2027), accompanied by an EBITDA-margin guide cut. That would prove the growth never inflected and the margin story was partly cosmetic — the multiple would then de-rate toward the low-ROIC peers (~12–13x), and the bull case is dead.

For the bear case to work:

• Organic growth must stay structurally flat (2% or less) even after pruning ends, exposing the business as a low-growth, ~8%-ROIC industrial overpaying-for-its-own-story at ~21x forward earnings.
• The margin program must plateau or require ever-larger restructuring to sustain, revealing the adjusted-EPS quality gap.
• The multiple must compress toward the low-ROIC water names.
• Falsification test: two consecutive quarters of ≥4% organic growth with EBITDA margin tracking the high end of guidance and restructuring charges declining — that would prove the demand inflection is real and the margin durable, validating the quality-compounder thesis and likely re-rating the stock back toward the mid-$140s+. The bear case is then wrong.

15. Source Appendix

See the Source Appendix (Appendix B) for the full source list. Primary sources: Xylem 10-K filings (FY2021–FY2025), 10-Q filings, 8-K material-event filings, the DEF 14A proxy (2026), Form-4 insider filings, and the Evoqua S-4 — all from SEC EDGAR (CIK 1524472). Quantitative data cross-checked against third-party financial-data providers (financials, ratios, enterprise value, valuation multiples, price/valuation history, factor loadings) and reconciled to the filings. Q1-2026 earnings-call transcript (April 28, 2026). Industry/regulatory context: ASCE Infrastructure Report Card, EPA (PFAS MCL, Lead & Copper Rule Improvements, SRF funding), IIJA/CRS, and water-equipment market research (Grand View, Fortune Business Insights). Peer comps from public financial data.

APPENDIX A — Standard Diligence Questionnaire

Xylem Inc. (NYSE: XYL) · As of June 27, 2026 · Supplemental diligence questionnaire.

General

What thoughtful questions have other investors asked about this company? The recurring institutional questions are: (1) Is the margin-expansion story (80/20 simplification, Evoqua synergies) durable, or is it being purchased with rising restructuring charges? (2) When does organic growth reaccelerate — and is the deliberate “walk-away” of low-margin revenue masking weak underlying demand? (3) Was the $6.9B Evoqua acquisition value-accretive, given it diluted owners ~24% and drove blended ROIC to ~8%? (4) Can the water-AMI refresh cycle (Sensus) actually inflect toward 2030? (5) Does the stock deserve a quality-industrial multiple given it earns the lowest ROIC in its peer set? These map directly to the valuation, variant-perception, and what-must-be-true analysis.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Mid-cycle, trending up on margin. Revenue/organic growth is at a cyclical low (flat organic, China −30%, deliberate pruning), while margins are at a structural high and rising (EBITDA 21% → guide 23%). The combination means earnings are depressed on volume but expanding on mix/productivity — adjusted EPS is growing despite flat revenue. Interpretation: earnings are neither at a clean cyclical high nor low; the volume line is troughing while the margin line compounds.

Driven by external environment or internal actions? Predominantly internal — the margin gains come from the company’s own 80/20 simplification and Evoqua integration, not from a demand boom. The flat top line is partly self-inflicted (walk-away). This is an unusually management-controlled earnings profile for an industrial.

How stable are revenues? Highly stable in aggregate (~half municipal/utility, rate-recovered, essential; ~$4.7B backlog, book-to-bill >1). The cyclical exposure is concentrated in Applied Water (industrial/commercial/residential, ~$1.8B). Aggregate revenue is among the most defensive in the industrial complex.

Outlook for products/services; how big is the market? A ~$71–75B global water-equipment market growing ~5%, with Xylem’s broader served market larger. Secular, multi-decade replacement runway (aging infrastructure, PFAS/lead mandates, AMI digitization). Growing, global, defensively positioned — but mid-single-digit growth, not high-growth.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Roughly stable; slowly consolidating via M&A. Segment-specific competition (Grundfos/KSB/Pentair in pumps, Badger Meter/Itron/Mueller in metering) is persistent but not intensifying dramatically. Scale and specification advantages are durable in the best franchises.

How profitable is the business (ROIC, ROE)? ROIC ~8% (FY2025) — the lowest in its flow-control peer set, depressed by Evoqua goodwill. ROE ~28% is a goodwill/thin-equity artifact, not a true return signal. Incremental operating margins (~54% in 2025) and returns on tangible capital are far better; the blended return on the full capital base is only ~cost of capital. Use ROIC + EV/EBITDA + FCF, not ROE.

How profitable is the industry; barriers to entry? Moderately profitable (~20–25% EBITDA margins for the quality players). Barriers are franchise-specific (brand specification, regulatory approvals, installed-base service networks, AMI network lock-in) rather than industry-wide — a fragmented industry with pockets of defensibility.

Can the business be easily understood? Yes — it sells water pumps, meters, treatment equipment, analytics, and services to utilities and industrials. Four clean segments. Understandable.

Can it be undermined by foreign low-cost labor? Partially in commoditized components/pumps, where regional OEMs compete on price. The specified, branded, regulated, installed-base franchises (Flygt, Sensus, Wedeco) are well-insulated. Net: low-to-moderate exposure.

Do brands matter? Yes — meaningfully. Flygt, Bell & Gossett, Goulds, Sensus, Wedeco are specified by name by engineers and municipalities; the brand is often better-known than “Xylem.” Brand-and-specification is a core part of the (narrow, per-franchise) moat.

Nature of competition / customers’ switching costs? Competition is on specification, reliability, service network, and total cost of ownership more than headline price (in the branded lines). Switching costs are real where there is installed-base service lock-in (Flygt parts/service) and network commitment (Sensus AMI) — but low in commoditized lines.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The installed base and service relationships (the source of recurring revenue) are not capitalized — a genuine economic asset understated on the books. Conversely, the $8.3B goodwill + $2.3B intangibles (mostly Evoqua) are large book assets whose economic value depends on synergy/return realization.

Off-balance-sheet liabilities? Nothing unusual flagged — operating leases, pension (~$317M), standard warranty/environmental reserves. No material hidden leverage.

How conservative is the accounting? Mixed. Cash conversion is high-quality (FCF >100% of net income), but the adjusted-EPS bridge is aggressive in one respect: it excludes rising restructuring charges (FY25 ~$103–133M, +66% YoY) as “one-time” even as they recur annually. Intangible-amortization add-backs are defensible (non-cash). Treat adjusted EPS with skepticism on the restructuring line.

How CapEx-hungry? Light — capex ~3–4% of revenue (~$280–370M/yr). The business funds dividend + buyback + tuck-in M&A internally from FCF. Not capital-intensive.

Capital Allocation & Management

How much FCF; how is it used; what is the philosophy? ~$0.9–1.0B FCF/yr (target “low-double-digit FCF margin”). Uses: growing dividend (~$1.60/sh, ~41% payout, +8% Jan-2026), a newly-activated $1.5B buyback ($581M in Q1-2026), and ~$1B/yr of tuck-in M&A. Philosophy (stated): balanced capital allocation, leverage managed 0.5–1.0x, opportunistic buybacks into dislocation.

Significant acquisitions recently? The defining one: Evoqua (May-2023, ~$6.9B all-stock, ~70% goodwill, +58.8M shares). Plus a $219M German water-quality-instruments tuck-in (March-2026). On the sell side, an international metering divestiture (closing end Q2-2026).

Buying back shares? Yes — newly, after a decade of essentially none. $1.5B authorization (Feb-2026), $581M repurchased in Q1-2026, opportunistically into weakness. A genuine positive but a short track record.

Issuing large amounts of stock to insiders? No — equity dilution is from the Evoqua all-stock deal (one-time) and routine SBC (~$53M/yr, ~0.6% of cap), not egregious insider issuance.

Compensation policy / incentive alignment? Annual bonus on adjusted EBITDA margin + organic revenue + adjusted FCF margin; LTI on relative TSR + cumulative adjusted EPS. Critically: no ROIC/return-on-capital metric anywhere — a governance flag for a company that just deployed $6.9B on goodwill. CEO Pine FY2025 total comp ~$11.3M. Ownership is index-dominated (Vanguard 11.5%, BlackRock 10.0%).

Motivations of management? Margin/EPS-focused (per the incentive design), which aligns with the self-help thesis but not with return-on-capital discipline. Insiders are net sellers (~$77M of sales / 77 transactions vs 3 trivial buys over 5 years); only one genuine open-market purchase (a director, ~$141k, near the May-2026 lows). No CEO/CFO open-market buying.

Valuation & Market Data

ADR / MLP / K-1? No — a US-domiciled C-corporation (Delaware/D.C.), issues a standard 1099. No K-1, not an MLP, not an ADR.

Dividend policy? Modest and growing — ~$1.60/share (~1.4% yield), ~41% payout, multi-year growth record, +8% in Jan-2026. Well-covered by FCF.

How profitable is the business? ~21% EBITDA margin, ~15% operating margin, ~11% net margin, ~$1B FCF on ~$9B revenue — solidly profitable, with margins rising. Returns on capital (~8% ROIC) are the soft spot.

Is net income diverging from cash from operations? No problematic divergence — OCF consistently exceeds net income (cash conversion >100%), a quality marker. The divergence that matters is GAAP vs adjusted EPS (intangible amortization + restructuring add-backs), not net income vs cash.

Risks & Downside

What factors would cause the stock to decline? (1) Organic growth failing to reaccelerate after the walk-away rolls off (the key risk); (2) margin guide cut / restructuring revealed as recurring; (3) multiple compression toward low-ROIC peers; (4) a repeat of full-price dilutive M&A; (5) deeper China/Europe weakness; (6) tariff/metals-inflation margin squeeze.

Risk of catastrophic loss? Very low. Fortress balance sheet (~0.25–0.6x net leverage), diversified essential-product end-markets, ~$1B FCF. No realistic path to permanent capital impairment.

Chance of total loss? Negligible — investment-grade, cash-generative, diversified. The realistic risk is opportunity cost / modest drawdown (paying ~21x forward for a 2–4% grower), not ruin.

Recent News & Events

Has the business environment changed recently? Modestly. Near-term demand softened (flat organic, China −30%, soft Western Europe), while capital return inflected up ($1.5B buyback, +8% dividend, $1B debt issuance). The Jefferies upgrade to Buy ($140 PT, June-2026) reflects a view that the de-rating is an entry point. The structural demand drivers are unchanged.

Significant acquisitions / divestitures? $219M German water-quality-instruments acquisition (March-2026); international metering divestiture (closing end Q2-2026); $850M largest-ever WSS outsourced-water contract booked (April-2026).

Change in accounting policies? None material flagged.

Recent changes — new markets, facilities, management? New CEO Matthew Pine (eff. Jan-2024); two new C-suite roles announced (Q1-2026); ongoing 80/20 operating-model transformation; growing data-center water exposure (Applied Water DC orders in Q1-2026 exceeded all of FY2025).

APPENDIX B — Source Appendix

Xylem Inc. (NYSE: XYL) · CIK 0001524472 · As of June 27, 2026. Primary sources first; aggregated/third-party data reconciled to filings.

Primary — SEC filings (EDGAR, CIK 1524472)

• Form 10-K, FY2021–FY2025 (annual reports) — revenue, segment data, margins, goodwill/intangibles, restructuring disclosures, tax-rate reconciliation, risk factors. FY2025 10-K (filed Feb-2026); FY2023 10-K (filed Feb-2024, Evoqua purchase-accounting allocation).
• Form 10-Q, FY2021–Q1-2026 (15 filings) — quarterly financials, segment trends, balance sheet.
• Form 8-K, ~42 filings (2021–2026) — earnings releases; Evoqua merger announcement (Jan-23-2023) and close (May-24-2023); CEO succession (Decker → Pine, Sept-2023 / eff. Jan-1-2024); COO appointment (Pine, Dec-2022); restructuring plan (Jan-30-2025, $95–115M); $1.5B buyback authorization (Feb-25-2026); $1B senior-notes offering (May-29-2026, 5.20% due 2033 / 5.45% due 2036); international metering divestiture; quarterly dividend declarations.
• Form S-4 / S-4-A — Evoqua merger registration: 0.48 exchange ratio, 58.78M shares issued, ~$6.9B consideration, ~$4.8B goodwill + ~$1.8B intangibles.
• DEF 14A proxy (filed March-30-2026) — executive compensation (AIP: adjusted EBITDA margin + organic revenue + adjusted FCF margin; LTI: relative TSR + cumulative adjusted EPS; no ROIC metric), CEO Pine FY2025 total comp ~$11.3M, beneficial ownership (Vanguard 11.5%, BlackRock 10.0%).
• Form 3 / 4 / 5 (insider transactions, full 5-year corpus, 226 Form-4s) — 3 open-market purchases (code P) vs 77 sales over 5 years; the only meaningful buy: Director Jerome Peribere, 1,210 sh @ $116.61 (~$141k), May-4-2026.

Primary — company / investor materials

• Q1-2026 earnings-call transcript (April 28, 2026) — CEO Matthew Pine, CFO Bill Grogan: FY2026 guidance (revenue $9.2–9.3B, EBITDA margin 22.9–23.3%, adjusted EPS $5.35–5.60), 80/20 walk-away (~200bps organic drag, peaking 2026), China −30%, $850M outsourced-water contract, data-center order strength, AMI refresh-cycle framing, buyback/M&A capital-allocation commentary. Via ROIC.ai.
• Xylem Investor Day 2024 framework (mid-teens EPS-growth algorithm, $1B/yr M&A target) — referenced in the Q1-2026 call.
• Xylem corporate research — AI/data-center water-demand projections (xylem.com newsroom).

Quantitative / aggregated data (reconciled to filings)

• ROIC.ai — income statement, balance sheet, cash flow (FY2018–FY2025 + TTM); profitability ratios (ROIC, ROE, margins); enterprise value (market cap ~$29.1B, EV ~$30.6B, Q1-2026 TTM); valuation multiples (own-history EV/EBITDA, P/E, P/B, P/S range); peer comps (PNR, VLTO, BMI, MWA, ROP, DOV, IEX, AOS, FELE, GGG, ITRI); earnings-call transcript.
• AZI (azitrading.com) — 5-year adjusted price history (ATH $151.41 Oct-29-2025; current $116.45; 5-yr low $69.42 Jun-2022; 52-wk $105.92–$151.41); valuation_index own-history percentiles (composite ~28th, P/E 21.8th, P/B 6.5th, P/S 55.7th); news feed (Jefferies upgrade to Buy / $140 PT, June-25-2026).
• FactorsToday — factor loadings (beta ~0.91; Dividend Yield +0.23/+0.27, Small-Size +0.14, Growth −0.11, Oil-Price −0.16; no Momentum/Value/Quality loading); risk-adjusted track record (5-yr return ~+1.2%/yr, negative short-horizon Sharpe, rs_6m −15%, rs_peak −23%); related-stocks (industrial ETFs, MSA, AYI, MTZ).

Industry / regulatory context

• ASCE 2025 Infrastructure Report Card — US drinking water (C-) and wastewater (D+) grades; investment gap.
• EPA — PFAS drinking-water MCLs (compliance ~2029); Lead & Copper Rule Improvements (lead-service-line replacement); State Revolving Fund / Drinking Water funding.
• IIJA / Bipartisan Infrastructure Law and CRS analysis — ~$50B water funding, ~70% obligated, authorization expiry Sept-30-2026.
• Water-equipment market research — Grand View Research, Fortune Business Insights, Straits Research (market size ~$71–75B 2025, ~5% CAGR).

Note: Xylem is a US-domiciled C-corporation; standard 1099 (no K-1, not an MLP/ADR). All SEC primary documents are available on EDGAR.